<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="that hydroxychloroquine, which shares the same mechanism of action as" exact="chloroquine" post="but has a better safety profile and is frequently"/>
 <result pre="connective tissue disease, has a more potent anti-viral effect than" exact="chloroquine" post="in vitro. From the results of physiologically-based pharmacokinetic models,"/>
 <result pre="daily for four days reaches three times the potency of" exact="chloroquine" post="and is therefore a promising drug for both the"/>
 <result pre="clinical trials that are ongoing to study the efficacy of" exact="chloroquine" post="or hydroxychloroquine in CoViD-19 patients. Hydroxychloroquine is thus being"/>
 <result pre="that are ongoing to study the efficacy of chloroquine or" exact="hydroxychloroquine" post="in CoViD-19 patients. Hydroxychloroquine is thus being used in"/>
 <result pre="study the efficacy of chloroquine or hydroxychloroquine in CoViD-19 patients." exact="Hydroxychloroquine" post="is thus being used in Italy for the treatment"/>
 <result pre="such as baricitinib, since they block the downstream signaling of" exact="alpha" post="and beta IFN receptors. The situation is complicated by"/>
 <result pre="avoid contact with crowded places. Smart working is encouraged. 3-" exact="Chloroquine" post="and hydroxychloroquine seem to have some efficacy on SARS-CoV2"/>
 <result pre="with crowded places. Smart working is encouraged. 3- Chloroquine and" exact="hydroxychloroquine" post="seem to have some efficacy on SARS-CoV2 infection. 4-"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
</results>
